Fundraising Fox

Eyestem

1 known investors

Find your way into Eyestem

Eyestem is a cell therapy company developing a scalable platform for treating incurable diseases, with embedded manufacturing and quality processes. Its lead product, Eyecyte-RPE, is an RPE cell therapy for Dry Age-related Macular Degeneration (AMD) currently in a Phase 2 clinical trial.

BiotechDeep TechDigital Health

Investors · 1

Endiya PartnersHyderabadvia Ramesh Byrapaneni · led

Funding

SEC filings, press & company announcements
  • $6.4MSeries AAug 2022 · 3 sources

    Alkem (lead), Biological E (lead), Biological E. Limited (lead), Biological E. Limited (BE) (lead), Natco (lead), Endiya Partners, Kotak, Kotak Private Equity

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Eyestem Research Raises USD 10 Millionindia.entrepreneur.com · Aug 2025Eyestem Raises $6.4 Million In Series A Funding Round | Entrepreneurentrepreneur.com · Aug 2022eyestem: Eyestem raises Series A round from Biological E, Alkem and others - The Economic Timeseconomictimes.indiatimes.com · Aug 2022eyestem funding: Cell therapy startup Eyestem raises ₹51 crore from BE, Alkem & Natco - The Economic Timeseconomictimes.indiatimes.com · Aug 2022Cell therapy firm Eyestem raises funding from Endiya partnersbiospectrumindia.com · May 2021Eyestem raises second round of funding from Kotak Private Equitybiospectrumindia.com

Frequently asked questions

What does Eyestem do?
Eyestem is a cell therapy company developing a scalable platform for treating incurable diseases, with embedded manufacturing and quality processes. Its lead product, Eyecyte-RPE, is an RPE cell therapy for Dry Age-related Macular Degeneration (AMD) currently in a Phase 2 clinical trial.
Who are Eyestem's investors?
Eyestem's investors include Endiya Partners.